Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Has completed written informed consent~2. Is male or female~3. Is age 18 through 45 years on Study Day 0~4. Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar~5. Has general good health, confirmed by medical history and physical examination~6. Has a Body Mass Index (BMI) between 19 and 33~7. Agrees to complete a follow-up period of 182 days as required by the protocol~8. Females: Agrees to avoid pregnancy from 28 days prior to Study Day 0 through the follow-up period of 182 days. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses) must agree to avoid pregnancy using an acceptable method~9. Agrees to avoid elective surgery for the duration of the study~10. Agrees to stay in contact with the investigative site for the study duration~11. Completed simultaneous enrollment in Aeras Vaccine Development Registry protocol~Exclusion Criteria:~1. Acute illness on Study Day 0~2. Axillary temperature \>=37.5 degrees Celsius on Study Day 0~3. Evidence of significant active infection~4. Used immunosuppressive medication within 42 days before Study Day 0~5. Received immunoglobulin or blood products within 42 days before Study Day 0~6. Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0~7. Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study, or any other standard vaccine within 42 days before Study Day 0~8. Current chronic drug therapy including hormone replacement such as thyroxin, insulin~9. History or laboratory evidence of past, present or future possible immunodeficiency state which include any laboratory indication of HIV infection~10. History of allergic disease or reactions, including eczema~11. Previous medical history that may compromise safety of the subject in the study~12. Evidence of new acute illness that may compromise the safety of subject in the study~13. Evidence of chronic hepatitis~14. Inability to discontinue daily medications except contraceptives during study period~15. History of alcohol or drug abuse within past 2 years~16. Tobacco or cannabis smoking three or more days per week~17. Positive urine test for illicit drugs~18. History or evidence of any systemic disease on physical examination~19. History or evidence of active tuberculosis~20. Shared a residence within the last year with a individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis~21. All females: Positive urine pregnancy test during screening~22. Abnormal (per local laboratory parameters) chemistry and hematology parameters~23. QuantiFERON®-TB Gold evidence of Mtb infection~24. Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 AERAS-404 (Type: EXPERIMENTAL): H4 Antigen at 5 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56
- Cohort 2 AERAS-404 (Type: EXPERIMENTAL): H4 Antigen at 15 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56
- Cohort 3 AERAS-404 (Type: EXPERIMENTAL): H4 Antigen at 50 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56
- Cohort 4 AERAS-404 (Type: EXPERIMENTAL): H4 Antigen at 150 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56
- Cohort 5 AERAS-404 (Type: EXPERIMENTAL): H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer~2 doses at Study days 0 and 56

Based on this trial design, predict the completion outcome and termination type (if applicable).